Col IV and Fn distribution in prostatic adenocarcinoma and correlation of 67LR, MMP-9 and TIMP-1 expression with Gleason score.
OBJECTIVE
To assess the immunoreactivity of 5 proteins related to basement membrane (BM) and extracellular matrix in order to investigate whether any of them correlates with differentiation of prostatic adenocarcinoma (PAc). Two of these markers are collagen type IV (Col IV), the collagenous component of basement membrane, and fibronectin (Fn), an adhesion protein in extracellular matrix. Others are matrix metalloproteinase-9 (MMP-9), a type IV collagenase, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), which has a high affinity for MMP-9, and 67-kd laminin receptor (67LR), which belongs to the non-integrin laminin binding receptor family.


METHODS
Forty-three PAc cases with Gleason scores ranging between 5 and 10 and 10 benign prostatic hyperplasia (BPH) cases, the control group, were included in the study. Formalin-fixed and paraffin-embedded tissue slides from each case were immunostained with the avidin-biotin-peroxidase method. Immunoreactivity was determined by means of a scoring system similar to the Gleason scoring system.


RESULTS
Overexpression of Col IV, Fn, 67LR and MMP-9 was detected in PAc as compared with BPH, whereas no difference was determined in TIMP-1 expression. Among these, only 67LR correlated statistically with Gleason score.


CONCLUSIONS
Expression of 67LR in tumor cells was significantly increased in parallel to tumor grade. This may be useful in microscopic evaluation of PAc.
Işisağ
Aydin
A
Department of Pathology, Faculty of Medicine, Celal Bayar University, Izmir, Turkey. aydinisisag@superonline.com
Neşe
Nalan
N
Ermete
Murat
M
Lekili
Murat
M
Ayhan
Semin
S
Kandiloğlu
Ali Riza
AR
D000230:Adenocarcinoma / Q000737:chemistry / Q000473:pathology; D000368:Aged; D000369:Aged, 80 and over; D001485:Basement Membrane / Q000737:chemistry*; D016022:Case-Control Studies; D024141:Collagen Type IV / Q000032:analysis / Q000096:biosynthesis; D016326:Extracellular Matrix Proteins / Q000032:analysis* / Q000096:biosynthesis; D005340:Fibrinogen / Q000032:analysis / Q000096:biosynthesis; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000032:analysis / Q000096:biosynthesis; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis* / Q000096:biosynthesis; D011470:Prostatic Hyperplasia / Q000473:pathology; D011471:Prostatic Neoplasms / Q000737:chemistry* / Q000473:pathology*; D017474:Receptors, Laminin / Q000032:analysis / Q000096:biosynthesis; D012720:Severity of Illness Index; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000032:analysis / Q000096:biosynthesis
D024141:Collagen Type IV; D016326:Extracellular Matrix Proteins; D009363:Neoplasm Proteins; D017474:Receptors, Laminin; D019715:Tissue Inhibitor of Metalloproteinase-1; D005340:Fibrinogen; D020780:Matrix Metalloproteinase 9